Affordable Access

High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.

Authors
  • McIntyre, Peter B
  • Turnbull, Fiona M
  • Egan, Anne-Marie
  • Burgess, Margaret A
  • Wolter, Joanne M
  • Schuerman, Lode M
Type
Published Article
Journal
Vaccine
Publisher
Elsevier
Publication Date
Dec 02, 2004
Volume
23
Issue
3
Pages
380–385
Identifiers
PMID: 15530684
Source
Medline
License
Unknown

Abstract

There is increasing interest in prevention of pertussis in adults by vaccination, but little is known about the duration of the antibody response to pertussis, diphtheria or tetanus in reduced antigen content vaccines formulated for adult use. Follow-up of a clinical trial including 550 adults comparing responses to reduced antigen content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, or a licensed Td vaccine, provided the opportunity to evaluate this. Blood samples were collected at 0, 1, 12, 24 and 36 months following vaccination; of the original cohort of 550, 387 subjects (dTpa group N=310, Td+pa group N=77) were tested at month 36. Following a decrease in antibody levels against all vaccine antigens between one and 24 months following vaccination, levels stabilized during the third year, remaining higher at 36 months than pre-vaccination for all vaccine antigens. In particular, more than 90% of subjects remained seropositive for pertussis toxin and pertactin antibodies at 36 months after vaccination, suggesting ongoing protection against pertussis. Adult-formulated dTpa vaccines could replace Td for routine booster vaccination of older individuals.

Report this publication

Statistics

Seen <100 times